PLPC-DB™: A Validated Structural Immunological Platform with No Equivalent in Contemporary Oncology
PLPC-DB™ is a non-cellular, non-pharmacodynamic, non-genomic structural immunological platform.
It is not a conventional drug or an exploratory therapy.
The system is fully validated, technically closed, and designed for institutional transfer — requiring no hospitalization, no cold-chain logistics, and no systemic pharmacovigilance.
Strategic Immunotherapy Placement Graph showing the evolution from receptor-dependent therapies (ICIs, CAR-T) toward structurally activated, receptor-independent systems.
Positioning PLPC-DB as structurally activated and regulation-aligned (ICIs · EMA · COFEPRIS · 2018).
Technical Profile
- Dermal activation of APCs without receptor binding
- Lyophilized formulation; ambient-stable; non-cellular
- Cohort of patients with STIP-traceable documentation
- STIP schema linking lot, patient, biomarker and outcome
Documentation and Regulatory Status
- Full technical dossier in ICH eCTD format (Modules 1–5)
- CRF v13.1 with audited SAP and verified digital records
- Independent validation letter available under NDA
- Peer-reviewed publications in Q1 journals (e.g., Cancers, Biomedicines, IJMS, MethodsX)
- Editable Term Sheet and institutional coverage letter available
Strategic Entry Route
- Primary: Acquisition of 80–100% of the asset (preferred)
- Alternative: Exclusive license, minority equity, or institutional representation
- All routes subject to formal institutional evaluation
Institutional Contact – Immediate Action
Request Access to CTD, STIP, or Due Diligence Files
To request confidential access to the full technical documentation—including regulatory modules, STIP records, SAP reports, and strategic materials—submit your request using the form below or via email.
WebDoc v2.1 – June 2025